Publication Name	World Journal of Clinical Cases
Manuscript ID	88638
Country	China

Received	2023-11-10 04:12
Peer-Review Started	2023-11-10 04:12
To Make the First Decision
Return for Revision	2023-11-22 01:09
Revised	2023-12-05 11:10
Second Decision	2023-12-18 02:38
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2023-12-18 07:28
Articles in Press	2023-12-18 07:28
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2023-12-26 03:15
Publish the Manuscript Online	2024-01-02 09:08

ISSN	2307-8960 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Urology & Nephrology
Manuscript Type	Retrospective Study
Article Title	Efficacy and safety of Nafamostat mesylate in patients with end-stage renal failure
Manuscript Source	Unsolicited Manuscript
All Author List	Kun Liu and Zhen-Hua Li
ORCID	Author(s) ORCID Number Zhen-Hua Li http://orcid.org/0009-0005-1993-3403
Funding Agency and Grant Number
Corresponding Author	Zhen-Hua Li, MM, Chief Doctor, Department of Critical Care Medicine, General Hospital of The Yangtze River Shipping, Wuhan Brain Hospital, No. 5 Huiji Road, Wuhan 430015, Hubei Province, China. zhenh0911@163.com
Key Words	End-stage renal failure; Nafamostat mesylate; Effectiveness; Safety study; Chronic kidney diseases
Core Tip	End-stage renal disease refers to the terminal stage of the progression of various chronic kidney diseases, such as chronic nephritis, nephrotic syndrome, and tubulointerstitial disease. We aimed to evaluate the efficacy and safety of Nafamostat mesylate in patients with end-stage renal failure. Treatment of patients showing end-stage renal failure with Nafamostat mesylate can significantly improve therapeutic efficacy and has high safety and clinical value.
Publish Date	2024-01-02 09:08
Citation	Liu K, Li ZH. Efficacy and safety of Nafamostat mesylate in patients with end-stage renal failure. World J Clin Cases 2024; 12(1): 68-75
URL	https://www.wjgnet.com/2307-8960/full/v12/i1/68.htm
DOI	https://dx.doi.org/10.12998/wjcc.v12.i1.68

Full Article (PDF)	WJCC-12-68-with-cover.pdf
Full Article (Word)	WJCC-12-68.docx
Manuscript File	88638_Auto_Edited-YJP.docx
Answering Reviewers	88638-Answering reviewers.pdf
Audio Core Tip	88638-Audio core tip.m4a
Biostatistics Review Certificate	88638-Biostatistics statement.pdf
Conflict-of-Interest Disclosure Form	88638-Conflict-of-interest statement.pdf
Copyright License Agreement	88638-Copyright license agreement.pdf
Signed Informed Consent Form(s) or Document(s)	88638-Informed consent statement.pdf
Institutional Review Board Approval Form or Document	88638-Institutional review board statement.pdf
Non-Native Speakers of English Editing Certificate	88638-Language certificate.pdf
Peer-review Report	88638-Peer-review(s).pdf
Scientific Misconduct Check	88638-Bing-Gao CC-2.png
Scientific Editor Work List	88638-Scientific editor work list.pdf